CVS

SEC source: 0001127602-19-009281 · form4.xml · nonDerivative · entry 3

Flum Joshua Matthew · CIK 0001412223 · EVP, Corp Strategy & Bus Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,768

F3 · shares: Consists of Restricted Stock Units awarded pursuant to Issuer's 2017 Incentive Compensation Plan and its Performance-Based Restricted Stock Unit Plan. Restrictions lapse in three equal installments, commencing February 28, 2020.

SEC source: 0001127602-19-009281 · form4.xml · nonDerivative · entry 2

Flum Joshua Matthew · CIK 0001412223 · EVP, Corp Strategy & Bus Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,214

F2 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0001127602-19-009281 · form4.xml · nonDerivative · entry 1

Flum Joshua Matthew · CIK 0001412223 · EVP, Corp Strategy & Bus Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,946

F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0001127602-19-009282 · form4.xml · nonDerivative · entry 2

Hourican Kevin · CIK 0001741853 · EVP & President, CVS Pharmacy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,778

F2 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0001127602-19-009282 · form4.xml · nonDerivative · entry 1

Hourican Kevin · CIK 0001741853 · EVP & President, CVS Pharmacy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 311

F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0001127602-19-009283 · form4.xml · nonDerivative · entry 2

Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,023

F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0001127602-19-009283 · form4.xml · nonDerivative · entry 1

Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,038

F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0000947871-19-000285 · ownership.xml · nonDerivative · entry 3

Flum Joshua Matthew · CIK 0001412223 · EVP, Ent. Strategy & Digital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,768

F3 · shares: Consists of Restricted Stock Units awarded pursuant to Issuer's 2017 Incentive Compensation Plan and its Performance-Based Restricted Stock Unit Plan. Restrictions lapse in three equal installments, commencing February 28, 2020.

SEC source: 0000947871-19-000285 · ownership.xml · nonDerivative · entry 2

Flum Joshua Matthew · CIK 0001412223 · EVP, Ent. Strategy & Digital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,214

F2 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0000947871-19-000285 · ownership.xml · nonDerivative · entry 1

Flum Joshua Matthew · CIK 0001412223 · EVP, Ent. Strategy & Digital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,946

F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan.

SEC source: 0001127602-19-007139 · form4.xml · nonDerivative · entry 1

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,974

F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock unit awards.

SEC source: 0001127602-19-003734 · form4.xml · derivative · entry 3

Roberts Jonathan C · CIK 0001410515 · EVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 77,639 shares

Expires 2019-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/2/2013.

SEC source: 0001127602-19-003734 · form4.xml · nonDerivative · entry 2

Roberts Jonathan C · CIK 0001410515 · EVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,763.6311

F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan.

F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $62.93 and $65.30 per share.

SEC source: 0001127602-19-003734 · form4.xml · nonDerivative · entry 1

Roberts Jonathan C · CIK 0001410515 · EVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,402.6311

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-003741 · form4.xml · derivative · entry 4

MERLO LARRY J · CIK 0001194413 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 166,368 shares

Expires 2019-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/2/2013.

SEC source: 0001127602-19-003741 · form4.xml · nonDerivative · entry 2

MERLO LARRY J · CIK 0001194413 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,208.9407

F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan.

F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging from $62.91 and $65.29 per share.

SEC source: 0001127602-19-003741 · form4.xml · nonDerivative · entry 1

MERLO LARRY J · CIK 0001194413 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 496,576.9407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-001770 · form4.xml · derivative · entry 7

MERLO LARRY J · CIK 0001194413 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,368

Underlying: Common Stock · 166,368 shares

Expires 2019-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/2/2013.

SEC source: 0001127602-19-001770 · form4.xml · nonDerivative · entry 2

MERLO LARRY J · CIK 0001194413 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,208.9407

F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan.

F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $68.72 and $69.65 per share.

SEC source: 0001127602-19-001770 · form4.xml · nonDerivative · entry 1

MERLO LARRY J · CIK 0001194413 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 496,576.9407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-000695 · form4.xml · nonDerivative · entry 1

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: Gift to Anahata Foundation on or about December 28, 2018.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 10

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 665,982

F9 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2018 Trust were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 9

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2018 Trust

Disclosed balance after: 0

F9 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2018 Trust were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

F10 · ownership.nature: Represents shares held by a 2018 Trust for which the reporting person is the investment advisor.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 8

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,448

F7 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2016 Trust were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 7

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2016 Trust

Disclosed balance after: 0

F7 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2016 Trust were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

F8 · ownership.nature: Represents shares held by a 2016 Trust for which the reporting person is the investment advisor.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 6

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540,640

F5 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2018 GRAT were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 5

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2018 GRAT

Disclosed balance after: 0

F5 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2018 GRAT were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

F6 · ownership.nature: Represents shares held by a 2018 GRAT for which the reporting person is the sole trustee.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 4

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,838

F3 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2017 GRAT II were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 3

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2017 GRAT II

Disclosed balance after: 0

F3 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2017 GRAT II were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

F4 · ownership.nature: Represents shares held by a 2017 GRAT II for which the reporting person is the sole trustee.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 2

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,711

F1 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2017 Grantor Retained Annuity Trust ("GRAT") were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

SEC source: 0001127602-18-037330 · form4.xml · nonDerivative · entry 1

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2017 GRAT

Disclosed balance after: 0

F1 · shares: Shares that the Reporting Person previously reported as indirectly owned through a 2017 Grantor Retained Annuity Trust ("GRAT") were transferred to the Reporting Person's personal brokerage account on December 20, 2018.

F2 · ownership.nature: Represents shares held by a 2017 GRAT for which the reporting person is the sole trustee.

SEC source: 0001127602-18-035366 · form4.xml · nonDerivative · entry 1

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,869

F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock unit award.

SEC source: 0001127602-18-034850 · form4.xml · nonDerivative · entry 1

Denton David M · CIK 0001428718 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 402.9767

F1 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $79.72 and $80.54 per share.

SEC source: 0001127602-18-034855 · form4.xml · derivative · entry 5

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,989

Underlying: Common Stock · 93,989 shares

Expires 2026-02-18

F5 · derivative.exercise_date: Represents unvested Stock Appreciation Rights ("SARs") granted under the Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the Merger Agreement. These SARs vest on February 19, 2019.

SEC source: 0001127602-18-034855 · form4.xml · derivative · entry 4

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,741

Underlying: Common Stock · 192,741 shares

Expires 2027-02-16

F4 · derivative.exercise_date: Represents unvested Stock Appreciation Rights ("SARs") granted under the Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the Merger Agreement. These SARs vest in two substantally equal annual installments beginning on February 17, 2019.

SEC source: 0001127602-18-034855 · form4.xml · nonDerivative · entry 3

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,359

F3 · shares: Consists of CVS RSUs awarded pursuant to the Plan. Restrictions lapse on 11/28/2021.

SEC source: 0001127602-18-034855 · form4.xml · nonDerivative · entry 2

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,215

F2 · price: Includes (1) 80,722 CVS Health Restricted Stock Units ("RSUs") that were converted from Aetna Performance Stock Units ("PSUs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Plan") pursuant to the Merger Agreement and that vest on February 19, 2019; (2) 35,946 CVS Health RSUs that were converted from Aetna PSUs granted under the Plan pursuant to the Merger Agreement and that vest on February 17, 2020; and (3) 84,547 CVS Health RSUs that were converted from Aetna RSUs granted under the Plan pursuant to the Merger Agreement and that vest in three equal annual installments beginning on December 2, 2018.

SEC source: 0001127602-18-034855 · form4.xml · nonDerivative · entry 1

Lynch Karen S · CIK 0001333760 · EVP & Pres, Aetna Bus Unit

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,747

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 8

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2016 Trust

Disclosed balance after: 112,808

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

F8 · ownership.nature: Represents shares held by a 2016 Trust for which the reporting person is the investment advisor.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 7

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2018 Trust

Disclosed balance after: 12,534

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

F7 · ownership.nature: Represents shares held by a 2018 Trust for which the reporting person is the investment advisor.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 6

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2018 GRAT

Disclosed balance after: 217,802

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

F6 · ownership.nature: Represents shares held by 2018 GRAT for which the reporting person is the sole trustee.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 5

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2017 GRAT II

Disclosed balance after: 90,127

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

F5 · ownership.nature: Represents shares held by 2017 GRAT II for which the reporting person is the sole trustee.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 4

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By 2017 GRAT

Disclosed balance after: 89,726

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

F4 · ownership.nature: Represents shares held by 2017 Grantor Retained Annuity Trust ("GRAT") for which the reporting person is the sole trustee.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 3

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By CLAT

Disclosed balance after: 100,072

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

F3 · ownership.nature: Represents shares held in Charitable Lead Annuity Trust for which the reporting person is the investment advisor.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 2

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,985

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

SEC source: 0001127602-18-034857 · form4.xml · nonDerivative · entry 1

Bertolini Mark T · CIK 0001352552 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,308

F1 · shares: Consists of common stock issued as a pro rata portion of the retainer payable for the reporting person's 2018-2019 Board service, pursuant to the Registrant's 2017 Incentive Compensation Plan.

SEC source: 0001127602-18-034859 · form4.xml · nonDerivative · entry 2

FARAH ROGER N · CIK 0001112072 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,821

F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.

SEC source: 0001127602-18-034859 · form4.xml · nonDerivative · entry 1

FARAH ROGER N · CIK 0001112072 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,308

F1 · shares: Consists of common stock issued as a pro rata portion of the retainer payable for the reporting person's 2018-2019 Board service, pursuant to the Registrant's 2017 Incentive Compensation Plan.

SEC source: 0001127602-18-034861 · form4.xml · nonDerivative · entry 2

AGUIRRE FERNANDO · CIK 0001224983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,912

F2 · shares: Consists of common stock issued as a pro rata portion of the retainer payable for the reporting person's 2018-2019 Board service, pursuant to the Registrant's 2017 Incentive Compensation Plan.

SEC source: 0001127602-18-034861 · form4.xml · nonDerivative · entry 1

AGUIRRE FERNANDO · CIK 0001224983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,604

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of December 3, 2017 (the "Merger Agreement"), by and among CVS Health Corporation ("CVS Health"), Hudson Merger Sub Corp. (the "Merger Sub"), a wholly owned subsidiary of CVS Health, and Aetna Inc. ("Aetna"), on November 28, 2018 (the "Closing Date") the Merger Sub merged with and into Aetna (the "Merger"), with Aetna continuing as the surviving company of the Merger and as a wholly owned subsidiary of CVS Health. Pursuant to the Merger Agreement, on the Closing Date each share of Aetna common stock held by the reporting person was converted into the right to receive 0.8378 of a share of common stock of CVS Health and $145.00 in cash. The closing price of CVS Health's common stock on November 28, 2018 was $80.27 per share.